SummaryBackground: Despite prospective randomized control trials showing that beta blockers, aspirin, angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering agents improve survival rates after myocardial infarction (MI), these agents are routinely underutilized.Hypothesis: Our aim was to determine the frequency with which cardiologists at a government, university-affiliated teaching hospital prescribe aspirin, beta blockers, ACE inhibitors, calcium-channel blocking agents (CCBs), and lipidlowering agents in patients post MI. The patients were followed by their primary care physicians in this hospital after discharge. We evaluated changes in patients' medical management at an average of 24 months after discharge from the acute event.Methods: Clinical data relative to long-term use of life-saving drugs in 156 survivors of definite MI (WHO criteria) at a government, university-affiliated teaching hospital were analyzed over a 24-month follow-up period.Results: Over 90% of patients with acute MI were given aspirin and beta blockers at discharge. About 50% of these patients were given ACE inhibitors, only 25% were prescribed CCBs, and 21% were given lipid-lowering agents. At 24 months of follow-up, the percentage of patients receiving aspirin, beta blockers, and ACE inhibitors had fallen to 88% (p = 0.0408), 71% (p < 0.0001), and 43% (p = 0.1122), respec-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.